Get the Stockscreener App
1.04
0.00%
0.00
After Hours:
1.09
0.05
+4.81%
Cocrystal Pharma Inc stock is traded at $1.04, with a volume of 14,594.
It is up +0.00% in the last 24 hours and up +7.85% over the past month.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
See More
Previous Close:
$1.04
Open:
$1.04
24h Volume:
14,594
Relative Volume:
0.01
Market Cap:
$14.34M
Revenue:
-
Net Income/Loss:
$-8.83M
P/E Ratio:
-1.4223
EPS:
-0.7312
Net Cash Flow:
$-8.01M
1W Performance:
+0.97%
1M Performance:
+7.85%
6M Performance:
-5.02%
1Y Performance:
-31.58%
1-Day Range:
$1.02
$1.05
1-Week Range:
$1.01
$1.07
52-Week Range:
$0.8588
$2.67
Cocrystal Pharma Inc Stock (COCP) Company Profile
Name
Cocrystal Pharma Inc
Sector
Industry
Phone
(786) 459-1831
Address
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.04 | 14.48M | 0 | -8.83M | -8.01M | -0.7312 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-20 | Initiated | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Stock (COCP) Latest News
Enterprise value to revenue forward of Cocrystal Pharma, Inc. – NASDAQ:COCP - TradingView
Price to earnings forward of Cocrystal Pharma, Inc. – NASDAQ:COCP - TradingView
Price to sales forward of Cocrystal Pharma, Inc. – NASDAQ:COCP - TradingView
Price to book forward of Cocrystal Pharma Inc – LS:A3DWYX - TradingView
Cocrystal Pharma Inc Actuals & Estimates (NASDAQ:COCP) - TradingView
Cocrystal Pharma(COCP) Stock Options Chain | Quotes & News - Moomoo
COCP Forecast — Price Target — Prediction for 2027 - TradingView
8CC Forecast — Price Target — Prediction for 2027 - TradingView
Cocrystal Pharma Inc (COCP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cocrystal Pharma Company Profile & Introduction - Moomoo
Cocrystal Pharma Inc (COCP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cocrystal Pharma Inc (COCP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cocrystal Pharma Inc (COCP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cocrystal Pharma Inc (COCP) Institutional Confidence - TradingKey
Cocrystal Pharma Inc (COCP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cocrystal Pharma Inc (COCP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cocrystal Pharma Inc (COCP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cocrystal Pharma Inc (COCP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cocrystal Pharma Appoints New CEO to Lead Transition - The Globe and Mail
Cocrystal Pharma Appoints James Sapirstein as New CEO – Leadership Transition and Company Details - Minichart
Cocrystal Pharma appoints James Sapirstein as CEO with new compensation package By Investing.com - Investing.com South Africa
Cocrystal Pharma appoints James Sapirstein as CEO with new compensation package - Investing.com India
James Sapirstein becomes CEO of Cocrystal Pharma (NASDAQ: COCP) - Stock Titan
Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer - Moomoo
Cocrystal Pharma taps longtime biotech exec as its new CEO - The Business Journals
Cocrystal Pharma Inc. (COCP) Q1 2026 Earnings: Wider-than-expected Loss as R&D Pipeline ProgressesEarnings Whisper Number - newsline.com
Cocrystal Pharma (COCP) CEO awarded 235,000 stock options under 2025 plan - Stock Titan
Cocrystal Pharma (COCP) CEO James Sapirstein files initial Form 3 - Stock Titan
Cocrystal Pharma names James Sapirstein as CEO - The Pharma Letter
Cocrystal Pharma Inc. Announces CEO Changes - marketscreener.com
Cocrystal Pharma Names New CEO to Drive Antiviral Pipeline - TipRanks
Cocrystal Pharma names James Sapirstein as new CEO By Investing.com - Investing.com South Africa
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer - BioSpace
Cocrystal Pharma names James Sapirstein as new CEO - Investing.com
Veteran antiviral leader James Sapirstein to head Cocrystal Pharma (NASDAQ: COCP) - Stock Titan
Cocrystal Pharma Appoints James Sapirstein, Biopharma - GlobeNewswire
COCP: Presentation Highlights CDI-988 - Zacks Small Cap Research
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cocrystal Pharma (COCP) - The Globe and Mail
Noble Financial Maintains Cocrystal Pharma(COCP.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Cocrystal Pharma (COCP) proxy details board elections, pay and 2026 votes - Stock Titan
Cocrystal Pharma | 8-K: Current report - Moomoo
Cocrystal Pharma (COCP) Unveils Promising Antiviral Developments - GuruFocus
Cocrystal Pharma Reports Promising Pan-Viral Antiviral Activity - TipRanks
Cocrystal Pharma discovers new pan-viral inhibitors - BioWorld News
Cocrystal Pharma (NASDAQ: COCP) highlights pan-viral inhibitor data and Phase 1b progress - Stock Titan
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza - GlobeNewswire
COCP Q1 2026 Earnings: Wider Loss Than Expected as Pre-Revenue Biotech Advances PipelineEarnings Revision Upgrade - The Legal Advocate
Cocrystal Pharma Stock Slips: Why COCP’s Norovirus Bet Is Back in Focus - Bez Kabli
Cocrystal (COCP) Q1 2026 Earnings Miss by Significant: Key TakeawaysMargin Compression Risk - Newser
Why Is Cocrystal Pharma, Inc. (COCP) Stock Down Today? - Meyka
Cocrystal Pharma, Inc. 2026 Q1 Financials: Company Overview, Segment Information, and Going Concern Risks - minichart.com.sg
Cocrystal Pharma Inc Stock (COCP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cocrystal Pharma Inc Stock (COCP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | Director |
Feb 06 '26 |
Buy |
0.95 |
50,000 |
47,280 |
1,888,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 31 '25 |
Buy |
0.95 |
50,000 |
47,275 |
1,838,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 30 '25 |
Buy |
0.97 |
20,000 |
19,310 |
1,788,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 26 '25 |
Buy |
0.97 |
40,000 |
38,944 |
1,768,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 24 '25 |
Buy |
0.97 |
25,000 |
24,258 |
1,728,551 |
| FROST PHILLIP MD ET AL | Director |
Nov 26 '25 |
Buy |
0.99 |
4,000 |
3,975 |
1,703,551 |
| FROST PHILLIP MD ET AL | Director |
Nov 25 '25 |
Buy |
0.94 |
20,000 |
18,812 |
1,699,551 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):